Digital Therapeutics Patient Acquisition Agent
Digital Therapeutics Patient Acquisition Agent
The digital therapeutics (DTx) market is projected to reach $12 billion by 2026, yet most DTx companies still rely on static landing pages that fail to educate or convert. This AI agent engages visitors with conversational product education, qualifies them based on condition, treatment history, and eligibility, and captures high-intent leads for your clinical or commercial teams. Built for digital therapeutics companies managing chronic conditions like diabetes, hypertension, substance use, and behavioral health.
Digital Therapeutics Patient Acquisition Agent
Deploying an AI agent for DTx lead generation drives measurable improvements in patient acquisition, enterprise pipeline, and marketing efficiency.
Traditional healthcare web forms convert at 2-5%, but patients evaluating digital therapeutics often need more education before committing. Conversational AI agents achieve 15-28% conversion rates by answering questions about efficacy, safety, and insurance coverage in real time. For DTx companies where patient lifetime value can reach thousands of dollars, this improvement directly accelerates commercial traction. The global DTx market, valued at roughly $10 billion in 2025, rewards companies that can acquire patients efficiently.
Digital therapeutics companies spend heavily on paid media to drive awareness and enrollment. By replacing static landing pages with a conversational AI agent, DTx firms typically see a 2-3x improvement in conversion rate from the same ad spend. This translates to a 50-65% reduction in cost per qualified lead. With North America representing over 46% of the global DTx market, competition for patient attention is intense, making conversion efficiency critical.
B2B DTx sales to health plans and employers involve long evaluation periods. An AI agent that pre-qualifies enterprise leads, captures requirements like covered lives, therapeutic focus areas, and implementation timeline, and routes them to the right sales rep shortens the top of the funnel. Companies report that pre-qualified leads reach the demo stage 40-50% faster, which compresses deal cycles and improves sales team productivity.
Digital Therapeutics Patient Acquisition Agent
features
Specialized features that address the unique challenges of marketing and distributing digital therapeutics solutions.
Digital therapeutics span a wide range of conditions, from Type 2 diabetes to insomnia to opioid use disorder. The AI agent supports condition-specific conversation paths that ask clinically relevant screening questions and present the right product messaging for each therapeutic area, ensuring patients receive information that is directly relevant to their situation.
DTx companies sell to both patients (B2C) and health plans, employers, or providers (B2B). This agent detects visitor intent early in the conversation and routes them to the appropriate qualification path. A patient exploring treatment options sees a different flow than a benefits manager evaluating DTx solutions for their workforce.
Regulatory credibility matters in digital therapeutics. The agent can reference clinical trial outcomes, FDA clearance status, and peer-reviewed evidence within the conversation. This builds trust with both patients and enterprise buyers who need to see clinical validation before committing to a DTx platform.
Patient health information collected through the chatbot is encrypted and managed in full HIPAA compliance. Tars holds SOC 2 Type 2 certification and supports Business Associate Agreements, meeting the privacy requirements that DTx companies face when collecting condition-specific health data during the lead qualification process.
Digital Therapeutics Patient Acquisition Agent
Three steps to turn website visitors into qualified DTx enrollment leads.
Digital Therapeutics Patient Acquisition Agent
FAQs
The agent engages website visitors in a guided conversation that explains your DTx solution, answers common patient and provider questions, and collects qualification data like condition type, treatment history, and insurance status. It delivers structured, high-intent leads to your enrollment or sales team instead of raw contact form submissions.
Yes. Tars integrates with over 600 platforms, including Salesforce, HubSpot, Zendesk, and custom APIs through webhooks. Lead data can flow directly into your patient enrollment system, CRM, or marketing automation platform. You can also push data to Google Sheets or Slack for lightweight workflows.
Yes. Tars is HIPAA compliant, SOC 2 Type 2 certified, GDPR compliant, and ISO certified. The platform supports Business Associate Agreements, which is essential for DTx companies collecting protected health information like condition details, medication history, and insurance data during the qualification process.
Absolutely. The AI agent uses conditional logic to detect whether a visitor is an individual patient or an enterprise buyer like a health plan, employer, or provider organization. Each audience sees a different qualification flow with questions tailored to their specific needs and decision criteria.
Most digital therapeutics companies can have the agent live within a few days. The Tars platform provides configurable conversation flows that can be customized to your specific therapeutic areas, enrollment criteria, and branding without requiring any coding or engineering resources.
Yes. You can embed clinical trial results, FDA clearance details, peer-reviewed study citations, and outcome metrics directly within the conversation flow. This is especially effective for building trust with health plan evaluators and clinicians who require evidence-based validation before recommending a DTx solution.
The agent can be deployed on your company website as a widget or full-page experience, on WhatsApp for direct patient messaging, and on Facebook Messenger. Multi-channel deployment is particularly valuable for DTx companies running awareness campaigns across social media and paid search.
The global digital therapeutics market is valued at approximately $10 billion in 2025 and is projected to grow at over 23% CAGR through 2034. As competition intensifies, DTx companies that deploy conversational AI agents for lead generation gain a significant advantage in patient acquisition efficiency and enterprise pipeline velocity compared to those relying on static web forms and traditional outreach.
Privacy & Security
At Tars, we take privacy and security very seriously. We are compliant with GDPR, ISO, SOC 2, and HIPAA.
Email - sales@hellotars.com
.png)
%201.png)
%201.png)
